
    
      In the recommendation by the Asian PAcific Association for the Study of the Liver(APASL),
      antiviral drug is recommended to stop when HBeAg seroconversion has developed for more than 6
      months among HBeAg-positive patietns. For HBeAg-negative patients, the APASL consensus
      recommended stopping anti-viral treatment when HBV DNA remained undetectable for three
      separates occasion 6 months apart. Nontheless, approximately 25% to 50% of the patients still
      develop hepatitis relapse after stopping anti-viral therapy even if these recommendations are
      followed. In this study, the investigators aimed to investigated the off-treatment sustained
      response in chronic hepatitis B parients following the stopping anti-viral treatment
      guideline in Korea.
    
  